

# Prostate Cancer™

U P D A T E

Conversations with Urologic Oncology Investigators  
Bridging the Gap between Research and Patient Care

**EDITOR**

Neil Love, MD

**INTERVIEWS**

Anthony Zietman, MD

Nancy A Dawson, MD

**CME**  
Certified



Subscribe to Podcasts or download MP3s of this program at [ProstateCancerUpdate.com](http://ProstateCancerUpdate.com)

---

## *Prostate Cancer Update*

### A Continuing Medical Education Audio Series

---

#### OVERVIEW OF ACTIVITY

Approximately 220,000 new cases of prostate cancer are diagnosed yearly in the US, accounting for approximately one third of new cancer cases in men. Published results from clinical trials lead to the emergence of new surgical and radiation therapy techniques and therapeutic agents, along with changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — the practicing urologist, radiation oncologist and medical oncologist must be well informed of these advances. To bridge the gap between research and practice, this issue of *Prostate Cancer Update* features one-on-one discussions with radiation oncologist Dr Anthony Zietman and medical oncologist Dr Nancy A Dawson. By providing information on the latest research developments and expert perspectives, this CME activity assists clinicians with the formulation of up-to-date clinical management strategies.

#### LEARNING OBJECTIVES

- Evaluate the clinical implications of emerging clinical trial data in prostate cancer screening, surveillance, prevention and treatment, and incorporate these data into management strategies in the settings of localized and advanced disease.
- Counsel appropriately selected patients with prostate cancer about the availability of ongoing clinical trials.
- Inform patients with prostate cancer about the specific risks and benefits of local therapies.
- Assess existing data and emerging research on the choice and timing of endocrine therapy, and apply this evidence to patient care decisions in the adjuvant and metastatic settings.
- Communicate the benefits and risks of employing taxane-based chemotherapy regimens for patients with biochemically recurrent or symptomatic metastatic prostate cancer.
- Appraise emerging data on biologic therapies, and consider the future clinical applicability for the treatment of patients with advanced prostate cancer.

#### ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 1.5 *AMA PRA Category 1 Credit(s)*<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should review the CME information, listen to the CD and complete the Post-test and Educational Assessment and Credit Form located in the back of this booklet or on our website at [ProstateCancerUpdate.com](http://ProstateCancerUpdate.com).

***This program is supported by educational grants from AstraZeneca Pharmaceuticals LP and Sanofi-Aventis.***

---

Last review date: August 2008; Release date: August 2008; Expiration date: August 2009

## CME INFORMATION

# Prostate Cancer™

U P D A T E

### FACULTY AFFILIATIONS



**Anthony Zietman, MD**

Jenot and William Shipley  
Professor of Radiation Oncology  
Harvard Medical School  
Massachusetts General Hospital  
Boston, Massachusetts



**Nancy A Dawson, MD**

William M Scholl Professor of  
Medicine and Oncology  
Director, Genitourinary  
Oncology Program  
Lombardi Comprehensive Cancer  
Center at Georgetown University  
Washington, DC

### CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — **Dr Love** had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: **Dr Zietman** — Honorarium for Non-US Lecture: Ismar Healthcare NV. **Dr Dawson** — Consulting Agreement: Amgen Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Pfizer Inc, Sanofi-Aventis.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

---

*This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.*

If you would like to discontinue your complimentary subscription to *Prostate Cancer Update*, please email us at [Info@ResearchToPractice.com](mailto:Info@ResearchToPractice.com), call us at (800) 648-8654 or fax us at (305) 377-9998. Please include your full name and address, and we will remove you from the mailing list.

QUESTIONS (PLEASE CIRCLE ANSWER):

1. The Prostate Cancer Prevention Trial demonstrated that \_\_\_\_\_ significantly reduced the risk of prostate cancer.
  - a. Bicalutamide
  - b. Finasteride
  - c. Docetaxel
  - d. None of the above
2. When categorized by risk of recurrence, the vast majority of men diagnosed with early prostate cancer are in the \_\_\_\_\_ category.
  - a. Low-risk
  - b. Intermediate-risk
  - c. High-risk
3. To date, clinical trials comparing high versus conventional doses of radiation therapy demonstrate that \_\_\_\_\_-dose radiation therapy is more efficacious with regard to local control.
  - a. High
  - b. Conventional
4. Based on an analysis of the SEER database, Smith and colleagues reported that men who receive an LHRH agonist are at an increased risk of diabetes and premature cardiac events.
  - a. True
  - b. False
5. Preclinical evidence suggests that chemotherapy administered before hormonal therapy, versus after or concurrently with hormonal therapy, results in a superior outcome in the prostate cancer model.
  - a. True
  - b. False
6. The CALGB is conducting a Phase III study of docetaxel with versus without \_\_\_\_\_ in patients with hormone-refractory metastatic adenocarcinoma of the prostate.
  - a. Bevacizumab
  - b. Estramustine
  - c. Rituximab
  - d. ZD4054
7. Side effects associated with bevacizumab include which of the following?
  - a. Hair loss
  - b. Hypertension
  - c. Proteinuria
  - d. Wound-healing impairment
  - e. b, c and d
8. Which of the following agents are endothelin receptor antagonists?
  - a. Atrasentan
  - b. Bevacizumab
  - c. ZD4054
  - d. Both a and c
9. In a Phase III trial comparing two doses of ZD4054 versus placebo for patients with hormone-refractory prostate cancer, a significant improvement in overall survival was recorded among the patients who received ZD4054.
  - a. True
  - b. False
10. Which of the following side effects are associated with docetaxel?
  - a. Excessive tearing
  - b. Nail changes
  - c. Neutropenia
  - d. All of the above
  - e. None of the above
11. Studies of neoadjuvant hormone therapy have demonstrated a survival advantage for patients with high-risk prostate cancer.
  - a. True
  - b. False

## EDUCATIONAL ASSESSMENT AND CREDIT FORM

### Prostate Cancer Update — Issue 2, 2008

Research To Practice is committed to providing valuable continuing education for oncology clinicians, and your input is critical to helping us achieve this important goal. Please take the time to assess the activity you just completed, with the assurance that your answers and suggestions are strictly confidential.

#### PART ONE — Please tell us about your experience with this educational activity

**BEFORE completion of this activity, how would you characterize your level of knowledge on the following topics?**

4 = Very good 3 = Above average 2 = Adequate 1 = Suboptimal

Ongoing and proposed clinical trials of adjuvant chemotherapy for prostate cancer... 4 3 2 1  
Side effects and tolerability of docetaxel and impact on quality of life ..... 4 3 2 1  
Evaluation of the novel agents bevacizumab and ZD4054 in prostate cancer ..... 4 3 2 1  
Controversies in the use of proton beam radiation therapy for prostate cancer..... 4 3 2 1  
Metabolic changes during gonadotropin-releasing hormone agonist therapy..... 4 3 2 1

**AFTER completion of this activity, how would you characterize your level of knowledge on the following topics?**

4 = Very good 3 = Above average 2 = Adequate 1 = Suboptimal

Ongoing and proposed clinical trials of adjuvant chemotherapy for prostate cancer... 4 3 2 1  
Side effects and tolerability of docetaxel and impact on quality of life ..... 4 3 2 1  
Evaluation of the novel agents bevacizumab and ZD4054 in prostate cancer ..... 4 3 2 1  
Controversies in the use of proton beam radiation therapy for prostate cancer..... 4 3 2 1  
Metabolic changes during gonadotropin-releasing hormone agonist therapy..... 4 3 2 1

**Was the activity evidence based, fair, balanced and free from commercial bias?**

☐ Yes ☐ No

If no, please explain: .....

**Will this activity help you improve patient care?**

☐ Yes ☐ No ☐ Not applicable

If no, please explain: .....

**Did the activity meet your educational needs and expectations?**

☐ Yes ☐ No

If no, please explain: .....

**Please respond to the following LEARNER statements by circling the appropriate selection:**

4 = Yes 3 = Will consider 2 = No 1 = Already doing N/M = Learning objective not met N/A = Not applicable

**As a result of this activity, I will be able to:**

- Evaluate the clinical implications of emerging clinical trial data in prostate cancer screening, surveillance, prevention and treatment, and incorporate these data into management strategies in the settings of localized and advanced disease. .... 4 3 2 1 N/M N/A
- Counsel appropriately selected patients with prostate cancer about the availability of ongoing clinical trials. .... 4 3 2 1 N/M N/A
- Inform patients with prostate cancer about the specific risks and benefits of local therapies. .... 4 3 2 1 N/M N/A
- Assess existing data and emerging research on the choice and timing of endocrine therapy, and apply this evidence to patient care decisions in the adjuvant and metastatic settings. .... 4 3 2 1 N/M N/A
- Communicate the benefits and risks of employing taxane-based chemotherapy regimens for patients with biochemically recurrent or symptomatic metastatic prostate cancer. .... 4 3 2 1 N/M N/A
- Appraise emerging data on biologic therapies, and consider the future clinical applicability for the treatment of patients with advanced prostate cancer. .... 4 3 2 1 N/M N/A

**What other practice changes will you make or consider making as a result of this activity?**

.....  
.....

EDUCATIONAL ASSESSMENT AND CREDIT FORM (continued)

What additional information or training do you need on the activity topics or other oncology-related topics?

Additional comments about this activity:

May we include you in future assessments to evaluate the effectiveness of this activity?

☐ Yes ☐ No

PART TWO — Please tell us about the faculty for this educational activity

4 = Very good		3 = Above average		2 = Adequate		1 = Suboptimal		
Faculty	Knowledge of subject matter				Effectiveness as an educator			
Nancy A Dawson, MD	4	3	2	1	4	3	2	1
Neil Love, MD	4	3	2	1	4	3	2	1
Anthony Zietman, MD	4	3	2	1	4	3	2	1

Please recommend additional faculty for future activities:

Other comments about the faculty for this activity:

REQUEST FOR CREDIT — Please print clearly

Name: Specialty:

Professional Designation:

☐ MD ☐ DO ☐ PharmD ☐ NP ☐ RN ☐ PA ☐ Other:

Medical License/ME Number: Last 4 Digits of SSN (required):

Street Address: Box/Suite:

City, State, Zip:

Telephone: Fax:

Email:

Research To Practice designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

I certify my actual time spent to complete this educational activity to be \_\_\_\_\_ hour(s).

Signature: Date:

To obtain a certificate of completion and receive credit for this activity, please complete the Post-test, fill out the Educational Assessment and Credit Form and fax both to (800) 447-4310, or mail both to Research To Practice, One Biscayne Tower, 2 South Biscayne Boulevard, Suite 3600, Miami, FL 33131. You may also complete the Post-test and Educational Assessment online at [www.ProstateCancerUpdate.com/CME](http://www.ProstateCancerUpdate.com/CME).

# Prostate Cancer™

U P D A T E

<b>Editor</b>	Neil Love, MD
<b>Managing Editor</b>	Kathryn Ault Ziel, PhD
<b>Scientific Director</b>	Richard Kaderman, PhD
<b>Senior Director, Medical Affairs</b>	Aviva Asnis-Alibozek, PA-C, MPAS
<b>Writers</b>	Lillian Sklaver Poltorack, PharmD Douglas Paley
<b>Continuing Education Administrator for Nursing</b>	Sally Bogert, RNC, WHCNP
<b>Content Validation</b>	Margaret Peng Erin Wall Clayton Campbell
<b>Director, Creative and Copy Editing</b>	Aura Herrmann
<b>Creative Manager</b>	Fernando Rendina
<b>Graphic Designers</b>	Jessica Benitez Jason Cunnius Tamara Dabney Claudia Munoz
<b>Senior Production Editor</b>	Alexis Oneca
<b>Traffic Manager</b>	Tere Sosa
<b>Copy Editors</b>	Dave Amber Margo Harris David Hill Rosemary Hulce Kirsten Miller Pat Morrissey/Havlin Carol Peschke Susan Petrone
<b>Production Manager</b>	Tracy Potter
<b>Audio Production</b>	Frank Cesarano
<b>Web Master</b>	John Ribeiro
<b>Faculty Relations Manager</b>	Melissa Vives
<b>CME Director/CPD Director</b>	Isabelle Tate
<b>Contact Information</b>	Neil Love, MD Research To Practice One Biscayne Tower 2 South Biscayne Boulevard, Suite 3600 Miami, FL 33131 Fax: (305) 377-9998 Email: <a href="mailto:DrNeilLove@ResearchToPractice.com">DrNeilLove@ResearchToPractice.com</a> Email: <a href="mailto:CE@ResearchToPractice.com">CE@ResearchToPractice.com</a>
<b>For CME/CNE Information</b>	

---

Copyright © 2008 Research To Practice. All rights reserved.

The compact disc, Internet content and accompanying printed material are protected by copyright. No part of this program may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording or utilizing any information storage and retrieval system, without written permission from the copyright owner.

The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their

own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.

Any procedures, medications or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information and comparison with recommendations of other authorities.

# Prostate Cancer™

---

U P D A T E

Copyright © 2008 Research To Practice.  
This program is supported by educational grants from  
AstraZeneca Pharmaceuticals LP and Sanofi-Aventis.

## Research To Practice®

Sponsored by Research To Practice.

Last review date: August 2008  
Release date: August 2008  
Expiration date: August 2009  
Estimated time to complete: 1.5 hours